| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 01/03/2006 | US6982320 Cytokine receptor common gamma chain like |
| 01/03/2006 | US6982319 Protein for use in the treatment of liver disorders, fibrosis, cancer, rheumatoid arthritis and glomeronephritis |
| 01/03/2006 | US6982318 Production of motif-specific and context-independent antibodies using peptide libraries as antigens |
| 01/03/2006 | US6982317 C21 polypeptide that modulates the stability of transcriptional regulatory complexes regulating nuclear hormone receptor activity |
| 01/03/2006 | US6982314 Lawsonia intracellularis proteins, and related methods and materials |
| 01/03/2006 | US6982246 oligopeptides comprising a sequence associated with HLA-B alpha 1 domain, but comprising a tyrosine-tyrosine-tryptophan triad; preventing organ transplant rejection; side effect reduction so the patient can still fight infections |
| 01/03/2006 | US6982160 Immunogenic compositions that include SIRS virus |
| 01/03/2006 | US6982156 comprises antibodies against Smallpox Inhibitor of Complement Enzyme (SPICE) or Vaccinia Virus Complement Control Protein (VCP); dna vaccines |
| 01/03/2006 | US6982149 Fiber array and methods for using and making same |
| 01/03/2006 | US6982089 Cytokine antagonists for neurological and neuropsychiatric disorders |
| 01/03/2006 | US6982084 An immunogenic A beta fragment linked to a carrier molecule to form a conjugate, wherein the carrier molecule promotes an immune response comprising antibodies to the A beta fragment; Alzheimer's disease; antibodies |
| 01/03/2006 | CA2162586C Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
| 01/01/2006 | CA2512493A1 Methods for assessing and treating cancer |
| 01/01/2006 | CA2502425A1 Allergen from house-dust mites |
| 12/30/2005 | CA2511084A1 Carbohydrate-phosphorylcholine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications |
| 12/29/2005 | WO2005124358A2 Diagnosis and treatment of siglec-6 associated diseases |
| 12/29/2005 | WO2005124352A2 Method for determining aggrecanase activities |
| 12/29/2005 | WO2005124346A1 4-1bb receptors are expressed on regulatory t-cells |
| 12/29/2005 | WO2005123922A1 Porcine sulfotransferase 2a1 polynucleotide sequence, protein, and methods of use for same |
| 12/29/2005 | WO2005123780A2 Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| 12/29/2005 | WO2005123779A2 Antibodies binding to cd34+/cd36+ fetal but not to adult cells |
| 12/29/2005 | WO2005123778A2 Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
| 12/29/2005 | WO2005123777A2 Method of treating granuloma annulare or sarcoid |
| 12/29/2005 | WO2005123776A1 Methods for treating conditions associated with lectin-dependent complement activation |
| 12/29/2005 | WO2005123775A1 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof |
| 12/29/2005 | WO2005123774A2 Antibodies to west nile virus polypeptides |
| 12/29/2005 | WO2005123773A1 Method for site-directed immunisation |
| 12/29/2005 | WO2005123772A2 Anti-cancer therapy |
| 12/29/2005 | WO2005123141A2 Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent |
| 12/29/2005 | WO2005123129A2 Methods of redistributing apical target antigens to detect and treat cellular proliferative disease |
| 12/29/2005 | WO2005123128A2 Methods for treating conditions associated with masp-2 dependent complement activation |
| 12/29/2005 | WO2005123126A2 Antibodies against human interleukin-13 and uses therefor |
| 12/29/2005 | WO2005122741A2 Antibodies against west nile virus and therapeutic and prophylactic uses thereof |
| 12/29/2005 | WO2005116077A3 LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY |
| 12/29/2005 | WO2005094364A3 Iga antibody protein as a cytotoxic drug |
| 12/29/2005 | WO2005079398A3 Drug conjugates |
| 12/29/2005 | WO2005077978A3 Antibody for diagnosing and treating neuropsychiatric diseases, in particular schizophrenia, depression and bipolar affective disorders |
| 12/29/2005 | WO2005077130A3 A method for the removal of aggregate proteins from recombinant samples using ion exchange chromatography |
| 12/29/2005 | WO2005074604A3 METHODS OF DETECTING Lp-PLA2 ACTIVITY |
| 12/29/2005 | WO2005065121A3 Methods and compositions for the production of monoclonal antibodies |
| 12/29/2005 | WO2005062893A3 Anti-cd52 antibody treatment for diabetes |
| 12/29/2005 | WO2005061542A3 Detection of cd20 in transplant rejection |
| 12/29/2005 | WO2005058244A3 Novel anti-dc-sign antibodies |
| 12/29/2005 | WO2005051178A3 Marker for neuromyelitis optica |
| 12/29/2005 | WO2005023996A3 METHODS OF INDUCING THE EXPRESSION OF BONE MORPHOGENETIC PROTEINS (BMPs) AND TRANSFORMING GROWTH FACTOR-β PROTEINS (TGF-βs) IN CELLS |
| 12/29/2005 | WO2005013918A3 Compositions, methods and kits relating to poxvirus subunit vaccines |
| 12/29/2005 | WO2004111608A8 Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions |
| 12/29/2005 | WO2004091384A3 Erbb surface receptor complexes as biomarkers |
| 12/29/2005 | WO2004074437A3 Compositions and methods for cancer immunotherapy |
| 12/29/2005 | WO2004069166A3 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein |
| 12/29/2005 | WO2004058191A3 Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
| 12/29/2005 | WO2004045544A8 Autocrine growth factor receptor antibodies and methods |
| 12/29/2005 | WO2003072799A3 Brother of the regulator of imprinted sites (boris) |
| 12/29/2005 | WO2003071933A3 Novel compositions and methods for cancer |
| 12/29/2005 | WO2002099040A3 Igs as modifiers of the p53 pathway and methods of use |
| 12/29/2005 | WO2002033113A3 Protein-protein interactions in neurodegenerative diseases |
| 12/29/2005 | US20050289660 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 12/29/2005 | US20050288864 Intracellular antibodies |
| 12/29/2005 | US20050288492 Anti-activated RAS antibodies |
| 12/29/2005 | US20050288491 Super-humanized antibodies against respiratory syncytial virus |
| 12/29/2005 | US20050288487 Human mast cell-expressed membrane proteins |
| 12/29/2005 | US20050288248 Polypeptide; polyethylene glycolylated polypeptide; antidiabetic agents; side effect reduction |
| 12/29/2005 | US20050288225 Modulators of intracellular inflammation, cell death and cell survival pathways |
| 12/29/2005 | US20050288217 Method for enhancing or inhibiting insulin-like growth factor-I |
| 12/29/2005 | US20050288211 Chemokine inhibitors; for treatment of gout; for inhibiting migration of neutrophils involved in pathogenesis |
| 12/29/2005 | US20050287644 Methods for producing and culturing rabbit-mouse hybridomas and monoclonal antibodies secreted by rabbit-mouse hybridomas |
| 12/29/2005 | US20050287642 Efficient protein expression system |
| 12/29/2005 | US20050287635 RTD receptor |
| 12/29/2005 | US20050287630 Human antibodies derived from immunized xenomice |
| 12/29/2005 | US20050287628 System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| 12/29/2005 | US20050287618 Labeling or detecting of immobilized poly(amino acids), including peptides, polypeptides and proteins, on membranes and other solid supports; |
| 12/29/2005 | US20050287608 Diagnostic methods for protein profiling |
| 12/29/2005 | US20050287606 T1 receptor-like ligand I |
| 12/29/2005 | US20050287603 Modulation of bone development |
| 12/29/2005 | US20050287595 obtaining a sample from a patient; conducting mass spectrometric analysis on the sample in a manner effective to maximize analysis of peptide fragments contained therein and comparing mass spectrum profiles of biopolymer marker and sample peptide |
| 12/29/2005 | US20050287588 Breast cancer specific gene 1 |
| 12/29/2005 | US20050287584 Secreted proteins encoded by human chromosome 13 |
| 12/29/2005 | US20050287582 Antibodies that specifically bind to FDF03 |
| 12/29/2005 | US20050287547 Embryonic stem cell markers and uses thereof |
| 12/29/2005 | US20050287546 Novel proteases |
| 12/29/2005 | US20050287538 Preparing a clone for producing an antigen-specific antibody by extracting genomic DNAs of lymphocytes from a mammalian immunized with a specific antigen; recovering variable regions of immunoglobulin, amplifying the variable regions using a frame-shifting PCR |
| 12/29/2005 | US20050287532 Methods for monitoring drug activities in vivo |
| 12/29/2005 | US20050287530 TCL-1b gene and protein and related methods and compositions |
| 12/29/2005 | US20050287529 Flea and tick octopamine receptor nucleic acid molecules, proteins and thereof |
| 12/29/2005 | US20050287521 Oligonucleotides from sequences coding for the surface component of ptlv envelope proteins and uses thereof |
| 12/29/2005 | US20050287170 Subunit vaccine against West Nile viral infection |
| 12/29/2005 | US20050287166 Malarial pre-erythrocytic stage polypeptide molecules |
| 12/29/2005 | US20050287165 Meningococcal antigens |
| 12/29/2005 | US20050287164 Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections |
| 12/29/2005 | US20050287163 Mycoplasma polypeptides |
| 12/29/2005 | US20050287155 Active agent has been modified by attachment of cell membrane-impermeabilizing group so that, if active agent so modified is cleaved from conjugate in blood plasma instead of inside target cell, the cell membrane-impermeabilizing group prevents or limits entry of modified active agent into cells |
| 12/29/2005 | US20050287154 Autophilic antibodies and method of making and using same |
| 12/29/2005 | US20050287153 Serum albumin binding peptides for tumor targeting |
| 12/29/2005 | US20050287151 Secreted protein therapeutics and uses thereof |
| 12/29/2005 | US20050287150 Antibodies against Clostridium difficile toxins and uses thereof |
| 12/29/2005 | US20050287149 Human monoclonal antibodies against bacillus anthracis protective antigen |
| 12/29/2005 | US20050287148 Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| 12/29/2005 | US20050287146 Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions |
| 12/29/2005 | US20050287145 Compositions and methods for producing vascular occlusion |
| 12/29/2005 | US20050287144 For the modulation of signal activities controlled by NF-kappa B-inducing kinase (NIK); cancer , rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, asthma, cardiac infarct, Alzheimer's disease, or atherosclerosis |